Search Results

SARNIA, ON / ACCESSWIRE / May 9, 2022 / Aduro Clean Technologies Inc. ('Aduro' or the 'Company') (CSE:ACT) (OTCQB:ACTHF) (FSE:9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into new-era resources and higher-value fuels, announces its membership in the Canada Plastics Pact (CPP). The CPP is part of the Ellen MacArthur Foundation's global Plastics Pact network, joining other plastics pacts across the world in a network of national and regional initiatives working towards the vision of a circular economy for plastics. The CPP brings together businesses, policy makers, and NGOs to work together and create a national solution to plastic waste and pollution through combined expertise, collaboration, and a desire to take action. "Waste plastic is a fast-growing global concern in need of innovative circular solutions that are practical, sustainable, and capable of driving real social-economic change. Aduro is proud to support the Canada Plastics Pact, as we strategically partner with industry and all levels of government to focus on commercialising low-carbon, circular approaches to upcycling plastics. Aduro knows that a circular economy for plastics is within reach. We look forward to working collaboratively across the value chain to implement chemical recycling of plastics with our patented Hydrochemolytic™ Technology process," says Ofer Vicus, Chief Executive Officer at Aduro. "Creating a circular economy for plastics packaging in Canada will require a collaborative effort by multiple stakeholders across the value chain. We are pleased to have Aduro Clean Technologies join the Canada Plastics Pact as a Signatory Partner, bringing their insight and expertise on how to overcome the limitations of traditional recycling with their innovative chemical conversion technology," says Sinead King, Director of Partnership Engagement at Canada Plastics Pact. About the Canada Plastics Pact The Canada Plastics Pact (CPP) is tackling plastic waste and pollution, as a multi-stakeholder, industry-led, cross-value chain collaboration platform. The CPP brings together Partners who are united behind a vision of creating a circular economy in Canada in which plastic waste is kept in the economy and out of the environment. It unites businesses, government, non-governmental organizations, and other key actors in the local plastics value chain behind clear actionable targets for 2025. The Canada Plastics Pact is a member of the Ellen MacArthur Foundation's Global Plastics Pact network. It operates as an independent initiative of The Natural Step Canada, a national charity with over 25 years experience advancing science, innovation and strategic leadership aimed at fostering a strong and inclusive economy that thrives within nature's limits. About Aduro Clean Technologies Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company's Hydrochemolytic™ technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into 21st-century resources. With funding and support from Bioindustrial Innovation Canada, the company has developed a pre-pilot reactor system to upgrade heavy petroleum into lighter oil. For further information, please contact: Ofer Vicus, CEO ovicus@adurocleantech.com Abe Dyck, Investor Relations ir@adurocleantech.com +1 604-362-7011 Investor Cubed Inc. Neil Simon, CEO nsimon@investor3.ca + 1 647 258 3310 Forward-Looking Statements This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events, or developments that the Company believes, expects or anticipates will or may occur in the future, are forward-looking statements. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Important factors that could cause actual results to differ materially from the Company's expectations include adverse market conditions and other factors beyond the control of the parties. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved, or disapproved the content of this news release. SOURCE

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 TORONTO, March 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19. On March 8th, 2023, the Company announced that it had received the Type C meeting written responses from the FDA to obtain agreement on the proposed protocol endpoints for the Company’s Study. The FDA recommended that the Company’s proposed primary symptom-based endpoint should cover the evaluation of time to sustained recovery assessed over an appropriate duration, evidence of subjects experiencing resolution of COVID-19 related symptoms and the element of sustained symptom resolution. After a further in-depth review and analysis of the FDA recommendations with members of the Company’s clinical trial team, including its statistician, regulatory affairs, medical affairs, and clinical research advisors, the Company has decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. As such, the Company will remain with the current Study protocol’s primary endpoint of proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization. Although the Study was originally designed for a ‘hospitalization or death’ primary endpoint, and it completed enrollment of almost three-quarters of the Study’s recruitment goal and recorded specific clinical symptoms (i.e. cough, fever, heart rate, and oxygen saturation), the Study was not designed to take into account all of the symptom assessments and supporting data outlined in the FDA guidelines to warrant a primary symptom-based endpoint for COVID-19 studies. With the shift in COVID-19 clinical outcomes observed over the course of the pandemic, many patients with COVID-19 were either asymptomatic or experienced mild to moderate illness and could be managed in the outpatient setting. The Company made efforts with the FDA to allow for specific primary symptom-based endpoints, which were aligned with the Study’s available Pre-Dose selection data, such as time to resolution from COVID-19 via the polymerase chain reaction test and proportion of participants with improvement in at least two COVID-19 related clinical symptoms on or before Day 14. As such, it was now determined by the Company’s advisors and clinical team that any deviation from the Study’s original primary endpoint (‘hospitalization or death’) and any unblinding of the Post-Dose selection data of approximately 500 subjects that were randomized in the current Study would jeopardize any chance of potential future regulatory approval. As previously announced, the Data Safety Monitoring Board (“DSMB”) reviewed the Study’s Post-Dose selection data and supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported. As a result, the Company is committed to advancing the clinical and commercial development of Bucillamine and plans to pursue the following activities: Continue discussions with the FDA on a pathway for future potential regulatory approval under the current Study’s objectives, which the FDA and DSMB continue to support; Work with the Study’s current participating clinical sites and potential new clinical sites to develop a defined recruitment plan that prioritizes subjects recognized to be at higher risk for developing severe COVID-19 to achieve the Study’s objectives; Determine potential opportunities of unblinding additional data related to the Study for evaluation to support future discussions with the FDA, and further studies for Long COVID or COVID symptom-related conditions, which the FDA provided advice to pursue, and various infectious and respiratory disorders; Develop reformulation strategies of Bucillamine to expand on its potential therapeutic utility targeting rare disorders that may come with regulatory incentives awarded by the FDA, such as orphan drug (i.e. ischemia-reperfusion injury, cystinuria), fast track, and breakthrough therapy designations; and Secure alliances with strategic partners, including pharmaceutical companies, to achieve Bucillamine’s full commercial potential. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time. About Revive Therapeutics Ltd. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com. For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: mfrank@revivethera.com Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2022, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. SOURCE

Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions. The company’s new focus on patients with Post COVID-19 Conditions, colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflects the compelling opportunity for apabetalone to benefit long-COVID patients along with guidance from the US Food and Drug Administration. Following the recent FDA meeting, Dr. Michael Sweeney, Senior VP, Clinical Development for Resverlogix, stated: “We are grateful to the FDA for the feedback and suggestions provided in our recent Type C meeting, and we look forward to continuing to work with regulators in our evaluation of apabetalone’s safety and efficacy in treating Post COVID-19 Conditions.” InvestmentPitch Media SOURCE

TORONTO, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SLHG; OTCQX: SLHGF) (“Skylight Health” or the “Company”), a healthcare platform combining technology and analytics, focused on transitioning patients into value-based care to drive better health outcomes and experiences in the United States, today announced a strategic commitment of USD 5 million in the form of a convertible debenture from a multi-billion dollar growth-oriented healthcare institutional investment firm in the United States. The investment is set to close in two tranches. The first tranche of USD 3.37 million has been completed as of the date of this release and the second tranche for the remaining USD 1.63 million is expected to close within 30 days. The investment is structured in the form of a 0% interest, asset-backed convertible debenture. Each debenture shall be in the principal amount of C$1,000. Each debenture shall be convertible into 1,111 common shares of the Company at C$0.90 (“Common Shares”). Upon issuance of the debenture, the holder shall also receive 1,111 share purchase warrants (the “Warrants”) of the Company. Each Warrant entitles the holder to purchase one Common Share (a “Warrant Share”) at a price of C$0.90 for a period of 5 years from the date of issuance of the Debentures. Skylight has the option to repay the debt at any time at their election, without penalty, regardless of the share price. The funds will be used to support Skylight on its pathway to profitability. Over the last 2 quarters, the Company has seen and reported an improved EBITDA performance while growing its top line revenue. Additionally, it has made several announcements where it has both expanded and added new Medicare Advantage Plans which will lead to new membership expected for 2023. Skylight’s Joint Venture with Centene Corp/Collaborative Health Systems will also allow its traditional Medicare patients to benefit from increased funding in the upcoming ACO Reach program in 2023. “Skylight structured this investment to reduce dilution to shareholders while giving the Company a significant buffer to execute on its vision,” said Prad Sekar, CEO and Co-Founder of Skylight Health. “We’ve continued to show increased revenue and decreased burn and expect to reach cash-flow-positivity in the upcoming quarters. We are excited to have a strong institutional investor who understands the long-term impact of our opportunity in the value-based care sector within US healthcare.” Northland Capital Markets acted as the sole placement agent for the financing. In connection with the financing, the Company paid a 7% cash finder’s fee to Northland. The convertible debenture and warrants are subject to final approval from the TSX Venture Exchange and all securities are subject to a standard four month plus one day hold period. In addition, the Board of Directors of the Company has authorized, and the Company has declared, a dividend on its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares (the “Series A Preferred Shares”) for the month of November 2022. The Series A Preferred Shares trade under the “SLHGP” stock ticker symbol. In accordance with the terms of the Series A Preferred Shares, the Series A dividend will be payable in cash in the amount of $0.1927 per share on November 21, 2022 to the shareholders of record of the Series A Preferred Stock as of the dividend record date of October 28, 2022. About Skylight Health Group Skylight Health Group (TSXV:SLHG; OTCQX: SLHGF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service (“FFS”) model to value-based care (“VBC”) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on the volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimizing unnecessary health expenditures that are not proven to maintain the patient’s well-being. This places emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices. Forward Looking Statements This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent our current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this release. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as "look forward," "believe," "continue," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings we make with the Canadian securities regulators, and Canadian Securities Administrators, available at www.sedar.com, and on our website, at skylighthealthgroup.com. For more information, please visit our website or contact: Investor Relations: Jackie Kelly investors@skylighthealthgroup.com 416-301-2949 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE

Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas New data on kt-3000 prototype lead candidate support novel bi-functional mechanism as a potential treatment for Ewing sarcoma and other soft-tissue tumors May 11, 2022 09:00 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the presentation of new data during the 2022 AACR Special Conference on Sarcomas in Montreal, Canada. Rakovina Therapeutics’ presentation entitled In vitro efficacy of a novel dual PARP-HDAC Inhibitor in Ewing sarcoma highlighted the Company’s development of its novel kt-3000 series drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tumors. “These newly presented in vitro data suggest promising activity for our novel kt-3000 series drug candidates as a potential treatment for Ewing sarcoma and other treatment-resistant cancers,” said Professor Mads Daugaard, PhD, president & chief scientific officer of Rakovina Therapeutics Inc. “Based on these outcomes, select kt-3000 candidates have now been advanced to evaluation of pharmacokinetics, safety and anti-tumour activity in vivo.” Ewing sarcoma is a cancer that occurs primarily in the bone or soft tissues and is the second most common type of bone cancer affecting children and young adults. Approximately thirty percent of patients will experience recurrence within five years following treatment. The prognosis for patients with recurrent or progressive Ewing sarcoma is poor with average survival from the time of relapse of only 14 months. Current treatments for Ewing sarcoma include chemotherapy, surgery and radiotherapy. Long-term side effects of these treatments can include heart and lung problems, emotional and learning difficulties, growth issues and secondary cancers associated with chemotherapy or radiation. The development of new and improved treatments for Ewing sarcoma represents a significant unmet medical need. FDA-approved poly(ADP)-ribose polymerase (PARP) inhibitors have previously been studied in clinical trials as a potential treatment for Ewing sarcoma but showed only limited clinical benefit. Pre-clinical studies have revealed the potential for synergy in the treatment of Ewing sarcoma by combining a PARP inhibitor with inhibition of histone deacetylase (HDAC) enzymes. In clinical practice, however, the benefits of combination treatments are often limited due to differing pharmacokinetics and overlapping toxicities requiring sequential administration. Rakovina Therapeutics’ kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both PARP and HDAC in a single molecule as a potentially more viable approach to providing meaningful clinical benefit to patients. New kt-3000 data presented by Rakovina Therapeutics’ researchers at the AACR Special Conference on Sarcomas demonstrate that: Rakovina Therapeutics’ kt-3283 prototype lead drug candidate exhibits potent bi-functional activity as evidenced by inhibition of PARP and PARylation at a low nanomolar potency plus potent inhibition of HDAC enzyme activity; kt-3283 treatment reduced viability of Ewing sarcoma cells >25 fold more potently than an FDA-approved PARP inhibitor or FDA-approved HDAC inhibitor; Treatment of Ewing sarcoma cancer cells with kt-3283 resulted in increased S-phase and G2/M cell cycle arrest compared to single-agent treatment with an FDA-approved PARP inhibitor or HDAC inhibitor, or the combination of the two PARP and HDAC inhibitors; and The kt-3000 bi-functional anti-cancer mechanism results in significantly higher DNA damage to Ewing sarcoma cancer cells compared to single-agent treatment with a PARP inhibitor or an HDAC inhibitor, both of which caused little or no DNA-damage to Ewing sarcoma cancer cells following equimolar treatment in the same assay. Rakovina Therapeutics has previously presented preclinical data at peer reviewed scientific meetings demonstrating the potential of kt-3000 series drug candidates against treatment-resistant cancer cell lines. Development of the kt-3000 series is supported, in part, by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults. Rakovina Therapeutics scientific presentations, including yesterday’s poster from the AACR Special Conference on Sarcomas can be found on the Company’s website. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com. Additional Information The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice regarding forward-looking statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. Contact: Rakovina Therapeutics Inc. David Hyman Chief Financial Officer Email: info@rakovinatherapeutics.com Investor Relations Contact IR@rakovinatherapeutics.com Media Contact MEDIA@rakovinatherapeutics.com SOURCE

Skylight Health Research continues to see success TORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ:SLHG;TSXV:SLHG) (“Skylight Health” or the “Company”), a healthcare platform combining technology, and analytics focused on transitioning patients into value based care to drive better health outcomes and experiences in the United States, today provides an update on the status of the Company’s research program; Skylight Health Research. In 2021, Skylight Health Group formally launched its research department; Since inception, Skylight Health Research has been awarded eleven (11) clinical studies and has completed four (4) to-date; Total revenue earned through clinical studies in 2021, $300,000, has been doubled in 2022; Skylight announces two new partnerships today, with Elligo Health Research® and Endominance. Skylight Health Research continues to see momentum and growth through 2022. Since the update in April 2022, two studies have been completed and one new study has been awarded. Four studies are currently ongoing at three clinics, and the newest study awarded will be conducted at three clinics launching in September 2022. Two awarded studies are on hold with the Sponsors and are pending launch. Continued success has been seen through Skylight’s partnership with ClinEdge. This vital partnership was expanded further in September 2021 when ClinEdge was acquired by Elligo. Elligo brings its own set of processes, efficiencies, and a wider group of research study opportunities to Skylight with their healthcare-enabling research model to participate in a variety of clinical studies. Skylight Health Research officially joined Elligo’s clinical research network in 2022 and has been working diligently to fully onboard all five clinics participating in Elligo’s Research Ready™ program. Skylight Health Research has also just recently partnered with Endominance for their Microbiome, Anxiety, & Cognitive Orientation (MACO) study to assist with their patient recruitment. The purpose of the MACO study is to better understand how gut bacteria may affect the brain and how they may be associated with anxious human behavior and cognitive traits. "This is a really fitting and seamless partnership for Skylight," says Alisha Garibaldi, VP of Clinical Research with Skylight. "The relationship between the microbiome and mental health has become a much more common topic lately, and the MACO study is investigating this complex relationship on a very large scale. We're excited to work with Endominance on a study that aligns so closely with Skylight's values and drive to contribute to the advancement of medical science." Research revenue in 2022 has more than doubled the $300,000 earned in 2021. The team continues to plan for further expansion to new markets within the company and is looking forward to a strong finish to 2022. About Skylight Health Group Skylight Health Group (NASDAQ:SLHG;TSXV:SLHG) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service (FFS) model to value-based care (VBC) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimize unnecessary health expenditures that are not proven to maintain the patient’s well-being. This places an emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices. Forward Looking Statements This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent our current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this release. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as "look forward," "believe," "continue," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings we make with the Canadian and United States securities regulators, including the Securities and Exchange Commission, available at: www.sec.gov, and Canadian Securities Administrators, available at www.sedar.com, and on our website, at skylighthealthgroup.com. For more information, please visit our website or contact: Investor Relations: Jackie Kelly investors@skylighthealthgroup.com 416-301-2949 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE

Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR) VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the acceptance of a new abstract to be presented at the 2022 AACR Annual Meeting. Rakovina Therapeutics’ abstract entitled Evaluation of a Novel Class of Bifunctional DNA Alkylating Agent and PARP Inhibitor will be presented at the in-person meeting, which is scheduled to be held April 8th-13th, 2022 in New Orleans, Louisiana. The AACR Annual meeting aims to connect scientists, clinicians, other health care professionals, cancer survivors and patient advocates from the international cancer research community and facilitate meaningful conversations regarding the full spectrum of cancer science and medicine. Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series. The company is developing three novel series of DNA-damage response (DDR) inhibitors as potential bio-marker driven treatments across multiple tumor types. Further information regarding the AARC General Meeting 2022 can be found at: https://www.aacr.org/meeting/aacr-annual-meeting-2022 About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com Additional Information The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice regarding forward-looking statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. Contact: Rakovina Therapeutics Inc. David Hyman Chief Financial Officer Email: info@rakovinatherapeutics.com Investor Relations Contact IR@rakovinatherapeutics.com Media Contact MEDIA@rakovinatherapeutics.com SOURCE #biotech #medicalscience #biotechnews #preclinical #cancerresearch #cancertherapeutics #DNAdamage #DDR #AACR #biotechstocks #preclinical #stockstowatch #pennystocks #FrontierMCG

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. To learn more about Rakovina Therapeutics Inc. please visit: https://www.rakovinatherapeutics.com Rakovina Therapeutics trades on the TSXV under the symbol: RKV

CLICK HERE TO READ THE FULL ARTICLE

Resverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment. The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study. For the full interview with Donald McCaffrey and to learn more about Resverlogix's study, click here. SOURCE

Resverlogix Corp. (TSX: RVX) is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners. The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They’re a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups. For more information: https://b-tv.com/resverlogix-the-futu... Subscribe to receive more investment opportunities videos: http://bit.ly/Subscribe2BTV Check out more videos: BTV Business Television episodes: http://bit.ly/2UBerea CEO Clips: http://bit.ly/2UTdumA New Listing Alert: http://bit.ly/2W1o0ob#Resverlogix #RVX #RVX SOURCE

v Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2B Trial for a Promising Canadian-Developed Covid-19 Treatment CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19. Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA. Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19. “Today is a landmark moment, as patients suffering from COVID-19 are now receiving apabetalone treatment for the first time,” said Donald McCaffrey, President & CEO of Resverlogix. “Additional Canadian sites in Calgary and Toronto will soon be coming online, as well as four new sites in Brazil, that will receive apabetalone supply this week. Due to the emergence of the Omicron variant, and the speed with which it has spread, adaptations to the trial have been made to greatly expedite full enrollment. A positive outcome in this trial will enable us to move quickly to deliver apabetalone to patients in need globally, thus providing critical and affordable help in the fight against the ongoing pandemic.” In the randomized, open-label trial, study participants will either receive twice daily oral doses of apabetalone or, alternatively, standard of care alone. A total of 100 patients are expected to be enrolled over the coming weeks, at multiple sites in Brazil and Canada. The primary outcome measure of the study will be a change in the WHO Ordinal Scale for Clinical Improvement – a standardized method of assessing COVID-19 disease severity on an 8-point scale. Secondary endpoints will include evaluating the effect of apabetalone on biomarkers of inflammation. A summary of the study protocol can be viewed HERE. “In addition to reducing the duration of the disease, the hope is that apabetalone will also potentially be able to protect those infected from the effects of chronic COVID-19 – often referred to as long-COVID – experienced months after the initial illness,” said Dr. Michael Sweeney, Senior Vice President, Clinical Development at Resverlogix. About Apabetalone Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes. Due to the extensive role for BET proteins in the human body, apabetalone, can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile – leading to a new way to treat chronic disease. Apabetalone received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA), and is the only drug of its class with an established safety record in human clinical trials, with well over 4200 patient-years on drug across 10 clinical trials. COVID-19: Following a publication in Nature, authored by a consortium of top Universities and Research Institutions, on March 23, 2020, Resverlogix launched a COVID-19 program, conducting research internally and enlisting world-renowned collaborators. Studies – published in prestigious scientific journals (including Cell) – demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual-mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage. A Phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19. The investigational treatment could potentially reduce the severity and duration of COVID-19. Apabetalone’s unique dual-mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. EVERSANA™ is currently leading clinical outreach and advocacy for apabetalone in the Canadian market. Cardiology: In February 2020, apabetalone became the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) – for a major cardiovascular indication – following the ground-breaking findings from the BETonMACE Phase 3 study. Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is commercializing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us: Twitter: @Resverlogix_RVX. LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/ Forward Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the Company’s Phase 2 clinical trial for the potential treatment of COVID-19 patients with apabetalone (and potentially other viruses), cardiovascular disease and associated comorbidities and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 www.resverlogix.com A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/d40d4d7b-24a7-477e-a175-67b8fca04802 SOURCE #biotech #biotechnews #apabetalone #science #medicalscience #clinicaltrials #covid19 #covidsolutions #biotechstocks #pennystocks #stockstowatch #FrontierMCG